An epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: Implication for herb-drug interaction

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Zhang, Zhang Jin ^a,b   Tan, Qing Rong ^b   Tong, Yao ^a   Wang, Xue Yi ^c   Wang, Huai Hai ^b   Ho, Lai Ming ^d   Wong, Hei Kiu ^a   Feng, Yi Bin ^a   di Wang, ^a   Ng, Roger ^e   McAlonan, Grainne M ^d   Wang, Chuan Yue ^f   Wong, Vivian Taam ^g  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e KOWLOON HOSPITAL   (Hong Kong)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g HOSPITAL AUTHORITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; HERBACEOUS AGENT;

ADULT; ADVERSE OUTCOME; AKEBIA CAULIS; ARTICLE; BUPLEURUM; CHINESE HERB; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG USE; FEMALE; GARDENIA; HERB DRUG INTERACTION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARANOID PSYCHOSIS; REHMANNIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHISANDRACEAE; SCHIZOPHRENIA; SEMEN PLANTAGINIS; STRUCTURED QUESTIONNAIRE; TREATMENT DURATION; URBAN AREA; CHINESE MEDICINE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; EVALUATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; QUESTIONNAIRE; UTILIZATION REVIEW;

AKEBIA; GARDENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DRUGS, CHINESE HERBAL; EPIDEMIOLOGIC STUDIES; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79951939709     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017239     Document Type: Article

References (36)

1. Fugh-Berman A, (2002) Herb-drug interactions. Lancet 355: 134-138.
2. Izzo AA, Ernst E, (2009) Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69: 1777-1798.
3. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL, (2004) Herbs and the kidney. Am J Kidney Dis 44: 1-11.
4. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, et al. (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387-391.
5. Yuen MF, Tam S, Fung J, Wong DK, Wong BC, et al. (2006) Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Aliment Pharmacol Ther 24: 1179-1186.
6. Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF, (2006) Drug-herb interactions: eliminating toxicity with hard drug design. Curr Pharm Des 12: 4649-4664.
7. Csernansky JG, Schuchart EK, (2002) Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16: 473-484.
8. Zhang ZJ, Tan QR, Zhen XC, Tong Y, (2010) The potential benefits of herbal medicines for schizophrenia: from empirical observations to clinical trials (chapter 16) In: Hertzman M, Adler L, editors. Clinical Trials in Psychopharmacology UK Wiley-Blackwell pp. 311-335.
9. Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, et al. (2008) A randomized crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 28: 264-370.
10. Peterson E, Stoebner A, Weatherill J, Kutscher E, (2008) Case of acute psychosis from herbal supplements. S D Med 61: 173-177.
11. Przekop P, Lee T, (2009) Persistent psychosis associated with salvia divinorum use. Am J Psychiatry 166: 832.
12. Zhang ZX, Zahner GE, Román GC, Liu XH, Wu CB, et al. (2006) Socio-demographic variation of dementia subtypes in China: Methodology and results of a prevalence study in Beijing, Chengdu, Shanghai, and Xian. Neuroepidemiology 27: 177-187.
13. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines.
14. Maciocia G, (1994) The practice of Chinese medicine: the treatment of diseases with acupuncture and Chinese herbs. Edinburgh, UK Churchill Livingstone pp. 342-385.
15. Xiang YT, Ma X, Cai ZJ, Li SR, Xiang YQ, et al. (2008) Prevalence and socio-demographic correlates of schizophrenia in Beijing, China. Schizophr Res 102: 270-277.
16. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS, (2007) Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 40: 47-52.
17. Chen Z, Gu K, Zheng Y, Zheng W, Lu W, et al. (2008) The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 14: 1049-1055.
18. Wu B, Liu M, Liu H, Li W, Tan S, et al. (2007) Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke 38: 1973-1979.
19. Ma K, Lee SS, Chu EK, Tam DK, Kwong VS, et al. (2008) Popular use of traditional Chinese medicine in HIV patients in the HAART era. AIDS Behav 12: 637-642.
20. Druss BG, Rosenheck RA, (1999) Association between use of unconventional therapies and conventional medical services. JAMA 282: 651-656.
21. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, et al. (1998) Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575.
22. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, et al. (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328: 246-252.
23. Bersani G, Valeri M, Bersani I, Piazza A, Adorno D, et al. (1989) HLA antigens and neuroleptic response in clinical subtypes of schizophrenia. J Psychiatr Res 23: 213-220.
24. Zalewski C, Johnson-Selfridge MT, Ohriner S, Zarrella K, Seltzer JC, (1998) A review of neuropsychological differences between paranoid and nonparanoid schizophrenia patients. Schizophr Bull 24: 127-145.
25. Fanous AH, Kendler KS, (2008) Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature. Curr Psychiatry Rep 10: 164-170.
26. Jablensky A, (2006) Subtyping schizophrenia: implications for genetic research. Mol Psychiatry 11: 815-836.
27. Tanaka A, Nishida R, Yoshida T, Koshikawa M, Goto M, et al. (2001) Outbreak of Chinese herb nephropathy in Japan: are there any differences from Belgium? Intern Med 40: 296-300.
28. Feng YB, eds. (2009) Basic and clinical toxicology of Chinese medicine (Chinese version). Hong Kong Public House of Commercial Affairs.
29. Deahl M, (1989) Betel nut-induced extrapyramidal syndrome: an unusual drug interaction. Mov Disord 4: 330-332.
30. Jones BD, Runikis AM, (1987) Interaction of ginseng with phenelzine. J Clin Psychopharmacol 7: 201-202.
31. Shader RI, Greenblatt DJ, (1985) Phenelzine and the dream machine-ramblings and reflections. J Clin Psychopharmacol 5: 65.
32. Zhang ZJ, Kang WH, Li Q, Tan QR, (2007) The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies. J Psychiatr Res 41: 828-836.
33. Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM, (2010) Atypical Antipsychotic Metabolism and Excretion. Curr Drug Metab 11: 516-25.
34. Wang B, Zhou SF, (2009) Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem 16: 4066-4218.
35. Ernst E, (2002) Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 23: 136-139.
36. Ernst E, (2004) Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 13: 767-771.